ASX-LISTED Bod Australia has announced that its partner, iX Biopharma Limited, has been granted an exclusive patent for its WaferiX drug delivery method by the People's Republic of China.
The approval provides Bod with patent protection for its finished sublingual cannabis wafer product which is to be tested in upcoming Phase I clinical trials.
Bod Australia ceo Jo Patterson said the addition of China meant the intellectual property was now protected in over 20 countries, providing the company with an "incredible opportunity to leverage the medicinal cannabis market," which is estimated to be worth more than US$55 billion annually.
The above article was sent to subscribers in Pharmacy Daily's issue from 27 Feb 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 27 Feb 18
